X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net financing will support the advancement of FB-102, which targets CD-122 and has demonstrated potentially best in class activity in graft versus host disease (GvHD).
Lead Product(s): FB-102
Therapeutic Area: Immunology Product Name: FB-102
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alger
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 01, 2023
Details:
Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
The primary endpoint of EASI-50 was achieved by 58% of subjects on FB-401 compared to 60% of subjects on placebo. Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint.
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and children.
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis (AD).
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
Forte Biosciences announced the issuance of its seventh U.S. patent (10,682,379), broadening protection to include methods for culturing gram negative bacteria from the skin.
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
As per the merger agreement, stockholders of Forte have become the majority owners of Tocagen, and the operations of Forte and Tocagen have combined.
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Forte Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 15, 2020
Details:
The acquisition includes Tocagen's retroviral replicating vector platform, investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC and several other development programs.
Lead Product(s): Vocimagene amiretrorepvec
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Denovo Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2020
Details:
The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator:
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Merger February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
